Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is a leading biopharmaceutical company with a strong focus on developing and marketing therapies for life-threatening infectious diseases. The recent acquisition of Arcellx, adding potential blockbuster CAR-T cell therapy anito-cel to Gilead's already strong portfolio of HIV and hepatitis drugs, provides a significant boost to the company's future potential revenue streams. Furthermore, Gilead's consistent financial performance, with solid revenue and income growth, combined with strategic investments and partnerships, make it a strong candidate for long-term growth and success in the healthcare sector.

Bears say

Gilead Sciences is facing potential risks to their revenue forecast, including increased competition from other companies in the biopharmaceutical industry, potential legal and regulatory challenges, and potential manufacturing and commercial challenges. Additionally, their forecasted sales for Yescarta are below market expectations, but this is offset by expected growth in the entire PrEP market. Despite a strong performance in their HIV franchise, Gilead's overall revenue growth is expected to be negatively impacted by policy changes and declining sales of Veklury. To counter this, Gilead has made strategic acquisitions in the oncology market, but concerns remain over the success of these acquisitions and the potential for further impairment charges. Looking forward, approvals and launches of potential key products such as Trodelvy and anito-cel in the next few years may provide upside, but competition in the CAR-T market could limit potential growth.

Gilead Sciences (GILD) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 14 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $155.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $155.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.